



Translational Medicine Research Associate to Associate Scientist

Position Summary

Pyxis Oncology is seeking a highly motivated, innovative, and collaborative research associate / associate scientist to join our Translational Medicine team. The successful candidate will support the characterization of human-relevant models, as well as many other aspects of translational medicine. The ideal candidate will be highly efficient and critical in their approach to science, with excellent interpersonal skills and team-centric mindset. The candidate must also enjoy the fast-paced, exciting, and ever-dynamic startup environment.

To apply, please email a cover letter and CV to Joan Resnicow at jresnicow@pyxisoncology.com.

Responsibilities

- Perform experiments using preclinical models such as human tumor/tissue explants coupled to downstream assays, including ELISA, histologic examination or bioinformatic analysis
- Provide translational data to program teams
- Organize and handle human and non-human tissue samples
- Work with CRO, vendor and external collaborator to advance programs
- Help set up translational lab infrastructure and workflow
- Draft SOPs for review

Qualifications

- Required:
 - Experience handling fresh or fixed solid tissue, including tissue dissociation, followed by downstream experiments or analyses
 - Experience in the following: ELISA, cell culture, flow cytometry
- Preferred:
 - Experience in handling human solid samples
 - Experience in any of the following disciplines: pathology, ex vivo culturing or computer programming
 - Familiarity with the following techniques: CRISPR, si/shRNA, western and qRT-PCR
 - Industry experience

About Pyxis

Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult-to-treat cancers. Built on the ground-breaking research of Dr. Thomas Gajewski, Pyxis is pursuing promising novel targets derived from the latest insights into the tumor microenvironment. Pyxis has generated preclinical data on these targets and is developing a pipeline of novel antibodies with the potential to help new patient populations not currently served by today's immunotherapies.